Supporting Investigator-Initiated Studies When Site Data Lives in PDFs, Scans and Mixed Formats
Investigator-initiated studies often rely on routine clinical records that were never designed for research. Planning for that reality at each stage, from proposal review to publication, is what separates studies that deliver from studies that stall.
Suhina Singh
Founder & CEO, Jonda Health
October 13, 2026
·
8 min read
The four stages at a glance
At each stage, this guide covers what to discuss, where data problems usually appear, and the practical options. Throughout, the investigator leads and the company supports within agreed terms.
Investigator-initiated studies are one of the most meaningful ways medical affairs teams support scientific inquiry. They let clinicians pursue the questions they see in their own practice, and they often produce the local, real-world insights that company-sponsored studies cannot. In much of Asia, they also depend heavily on routine clinical records: discharge summaries, laboratory reports, imaging reports and clinical notes that sit in PDFs, scans, paper files and several systems, sometimes in more than one language.
When a study stalls, it is rarely because the question was wrong. More often, the data turned out to be harder to find, read or combine than the proposal assumed, and the investigator's team ran out of time or budget to close the gap. Medical affairs teams who understand this can review proposals more realistically, and investigators who plan for it can protect their study. This guide walks through what good data practice looks like at each stage.
First, the boundary: supporting without directing
In an investigator-initiated study, the investigator (or their institution) is the sponsor. They own the research question, the protocol, the conduct of the study, the data and the decision to publish. The company's role is to review the proposal through its formal process and, where approved, provide support such as funding or product under a written agreement, in line with company policy, local regulations and industry codes.
Everything in this guide should be read in that light. Medical affairs teams can ask good questions about data feasibility during proposal review, and can expect investigators to show a credible plan. They should not design the study, choose vendors on the investigator's behalf, or influence how data is analysed or reported. The aim is a study that is both independent and able to deliver.
A simplified view. Company policies, agreements and local rules set the exact boundaries.
Stage 1
Feasibility and proposal review
This is the stage where a realistic view of the data costs least and changes most. A proposal can describe an elegant question and a sensible sample size, yet say little about whether the records needed to answer it exist in usable form. For medical affairs reviewers, asking about data feasibility is part of assessing whether a proposal can deliver, and it does not cross into directing the study.
Where problems usually appear
The sample size assumes every eligible patient has complete records, when key variables are often missing for a large share of patients.
Critical variables such as disease stage, treatment response or reasons for switching live only in clinical notes or scanned reports.
The study team has not yet looked at real records, so the effort needed to extract data is a guess.
Practical options
Investigators can strengthen a proposal by reviewing a small number of eligible records before submission, noting where each key variable is found and how complete it is. Where most variables sit in unstructured documents, the proposal should say how they will be extracted and by whom, and the budget should reflect it.
Questions to discuss during proposal review 1. Where are the key study variables recorded today, and in what formats and languages? 2. Has the team reviewed real records to confirm completeness, and what did they find? 3. Is the planned sample size realistic once incomplete records are excluded?
Stage 2
Set-up
Once a study is approved, the set-up stage decides whether the data will hold together. This is when the investigator's team turns intentions into a data management plan, a case report form that matches how information is actually recorded, and the approvals that allow the data to be used.
Where problems usually appear
The case report form asks for information in a form the source records do not hold, such as a numeric score that clinicians describe only in words.
Definitions are left open, so different abstractors interpret the same record differently.
Pseudonymisation, storage and processing location are decided late, delaying ethics or data protection approval.
The budget covers the analysis but not the work of preparing the data.
Practical options
A short data management plan helps even a small study: it defines each variable and where it comes from, how records will be pseudonymised at source, where data will be stored and processed, and how quality will be checked. Piloting the case report form on a handful of real records before full collection starts is one of the most effective ways to catch mismatches early.
Questions for the investigator's team to settle 1. Is every variable defined clearly enough that two people reading the same record would record the same value? 2. Where will data be pseudonymised, stored and processed, and does that meet local requirements? 3. Is data preparation included in the study budget and timeline?
Stage 3
Conduct
During conduct, the practical work of turning records into study data happens, and it is usually where time runs short. Research coordinators, residents and nurses often abstract data by hand alongside clinical duties. When records are long, scanned or multilingual, progress can slow sharply, and consistency between abstractors becomes hard to maintain.
Where problems usually appear
Abstraction takes far longer per patient than planned, and recruitment targets slip.
Different people interpret the same types of records differently, and nobody notices until analysis.
There is no clear record of where each value came from, which makes queries hard to resolve.
Practical options
Study teams broadly have three approaches to extraction. Each can work, and the right choice depends on volume, complexity and resources. What matters most is that clinical judgement is applied where interpretation is needed, and that every value can be traced back to its source.
A general comparison. Results depend on how each approach is set up and checked.
Questions for the investigator's team to track 1. How long is each patient record taking, and is that in line with the plan? 2. Who reviews values that need clinical interpretation, and how are disagreements resolved? 3. Can every value in the dataset be traced back to its source document?
Stage 4
Analysis and publication
By the analysis stage, the quality of earlier decisions becomes visible. A dataset that was defined clearly, extracted consistently and checked clinically can be analysed with confidence. One that was not will generate queries, delays and, sometimes, conclusions that reviewers challenge.
Where problems usually appear
Data from different sites or periods cannot be combined without further cleaning.
Reviewers or journals ask how variables were derived, and the answer is not documented.
The prepared dataset is discarded after publication, so the next study starts from scratch.
Practical options
Keeping a simple record of how each variable was extracted, cleaned and transformed makes analysis faster and publication smoother, and it supports the transparency that journals and data sharing statements increasingly expect. Where permissions allow, keeping the prepared dataset and its definitions for future approved research means the institution's effort continues to create value after the first paper.
Questions for the investigator's team to plan for 1. Is there a documented record of how each variable was derived? 2. What data sharing or reproducibility commitments does the target journal expect? 3. Can the prepared dataset be retained for future approved research, and under what permissions?
The stages at a glance
Use this table when reviewing a proposal or planning a study. It summarises what good looks like at each stage and the signals that a study may struggle.
Stage
What good looks like
Red flag
Feasibility
Real records reviewed; variable locations and completeness known
Sample size assumes complete records nobody has checked
Set-up
Clear definitions, piloted CRF, data plan and budget for preparation
CRF asks for information the records do not hold
Conduct
Clinical review of interpreted values; every value traceable
Abstraction far behind plan with no quality checks
Analysis
Derivations documented; dataset retained where permitted
Data cannot be combined or explained at review
How Jonda Health can help
Routine clinical records hold the answers to many important questions, and turning them into research-ready data is the work we focus on. We can support investigators and institutions directly, and we can work with medical affairs teams on how data readiness is considered across their programmes, always within the boundaries that keep investigator-initiated research independent.
Jonda Health Services
Plan data readiness with confidence
Through our Health Data Foundations work, we help investigators and institutions review real records, define variables, shape data management plans and estimate what preparing the data will take. For medical affairs teams, we can help build practical data feasibility questions into the way proposals are reviewed.
JondaX
Turn records into study data
When study data sits in PDFs, scans, images and mixed formats across more than 10 languages, JondaX turns it into structured, standardised information through a single API. Our clinically trained reviewers check the output, achieving 99% field-level accuracy with expert review. JondaX is ISO 27001 certified, designed to comply with HIPAA, GDPR and PDPA, and can be deployed and processed fully within a client's country where required.
Book a free 30-minute data readiness conversation
Whether you are reviewing proposals or planning your own study, bring your question and the records you expect to use, and we will talk through where the data risks are and how to address them.